Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria’s stockholders held on January 21, 2026, Astria’s stockholders voted to approve the acquisition of Astria...
Shareholders should contact the firm as there may be limited time to enforce your rights. Â
NEW YORK and NEW ORLEANS , Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating the...
NEW YORK , Dec. 19, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Â
NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...
NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Â
-- BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 -- -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned...
-- Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy,...